Free Trial
→ URGENT: This Altcoin Opportunity Won’t Wait – Act Now (From Crypto Swap Profits) (Ad) Buy CORZ Stock  Free CORZ Stock Alerts
Live Earnings Conference Call: Core Scientific will host a live Q1 2025 earnings call on May 7, 2025 at 4:30PM ET. Follow this link to get details and listen to Core Scientific's Q1 2025 earnings call when it goes live. Get details.

Core Scientific (CORZ) Financials

Core Scientific logo
$8.99 +0.25 (+2.80%)
Closing price 05/6/2025 03:59 PM Eastern
Extended Trading
$9.22 +0.22 (+2.45%)
As of 05/6/2025 07:59 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.
Compare
Annual Income Statements for Core Scientific

Annual Income Statements for Core Scientific

This table shows Core Scientific's income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric 2020 2021 2022 2023 2024
Period end date 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024
Net Income / (Loss) Attributable to Common Shareholders		 -18 47 -2,146 -246 -1,315
Consolidated Net Income / (Loss)		 -12 47 -2,146 -246 -1,315
Net Income / (Loss) Continuing Operations		 -18 47 -2,146 -246 -1,315
Total Pre-Tax Income 		-12 63 -2,163 -246 -1,314
Total Operating Income		 -6.33 131 -2,110 8.96 -19
Total Gross Profit		 9.39 239 8.40 123 121
Total Revenue		 54 544 640 502 511
Operating Revenue		 54 544 640 502 511
Total Cost of Revenue		 51 306 632 379 390
Operating Cost of Revenue		 51 306 632 379 390
Total Operating Expenses		 16 107 2,118 114 140
Selling, General & Admin Expense		 15 60 213 94 110
Marketing Expense		 1.77 4.06 13 7.02 9.97
Research & Development Expense		 5.27 7.67 27 7.18 12
Other Operating Expenses / (Income)		 - 0.00 0.00 0.03 3.81
Impairment Charge		 0.00 37 1,881 4.41 0.00
Other Special Charges / (Income)		 -5.88 -2.06 -16 1.96 4.21
Total Other Income / (Expense), net		 -5.88 -68 -54 -255 -1,295
Interest Expense		 1.33 8.02 0.29 -20 0.49
Interest & Investment Income		 -4.44 -44 -97 -86 -37
Other Income / (Expense), net		 -0.11 -16 43 -189 -1,257
Income Tax Expense		 0.00 16 -17 0.68 0.86
Basic Earnings per Share		 ($0.14) $0.23 ($6.30) ($0.65) ($4.39)
Weighted Average Basic Shares Outstanding		 157.60M 207.26M 340.65M 379.86M 255.83M
Diluted Earnings per Share		 ($0.14) $0.20 ($6.30) ($0.65) ($4.39)
Weighted Average Diluted Shares Outstanding		 157.60M 233.31M 340.65M 379.86M 255.83M
Weighted Average Basic & Diluted Shares Outstanding		 - 0.00 373.80M 177.60M 294.12M

Quarterly Income Statements for Core Scientific

This table shows Core Scientific's income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric Q3 2022 Q4 2022 Q1 2023 Q2 2023 Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024
Period end date 9/30/2022 12/31/2022 3/31/2023 6/30/2023 9/30/2023 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024
Net Income / (Loss) Attributable to Common Shareholders		 -435 -435 -0.39 -9.26 -41 -196 211 -805 -455 -266
Consolidated Net Income / (Loss)		 -435 -435 -0.39 -9.26 -41 -196 211 -805 -455 -266
Net Income / (Loss) Continuing Operations		 -435 -435 -0.39 -9.26 -41 -196 211 -805 -455 -266
Total Pre-Tax Income 		-424 -456 -0.28 -9.13 -41 -195 211 -805 -455 -265
Total Operating Income		 -401 -636 7.60 9.47 -12 3.93 55 6.58 -41 -40
Total Gross Profit		 -27 -47 32 37 15 39 78 39 -0.16 4.76
Total Revenue		 163 121 121 127 113 142 180 141 95 94
Operating Revenue		 163 121 121 127 113 142 180 141 95 94
Total Cost of Revenue		 190 168 89 90 97 103 102 102 96 90
Operating Cost of Revenue		 190 168 89 90 97 103 102 102 96 90
Total Operating Expenses		 374 589 24 27 27 35 23 32 41 44
Selling, General & Admin Expense		 43 39 22 24 24 24 14 26 34 36
Marketing Expense		 0.04 1.06 1.01 1.08 1.04 3.89 0.98 2.97 3.15 2.87
Research & Development Expense		 6.19 2.66 1.42 1.64 2.25 1.88 1.80 2.17 2.84 5.02
Other Operating Expenses / (Income)		 - - 0.00 0.00 0.00 0.03 2.22 1.12 0.21 0.26
Other Special Charges / (Income)		 -11 -4.32 -1.06 -0.76 -0.02 3.80 3.82 -0.27 0.51 0.15
Total Other Income / (Expense), net		 -23 180 -7.89 -19 -29 -199 156 -811 -414 -225
Interest & Investment Income		 -26 -22 -0.16 0.04 -2.20 -84 -14 -15 -7.07 -1.14
Other Income / (Expense), net		 3.17 202 -28 -19 -27 -114 170 -796 -407 -224
Income Tax Expense		 11 -21 0.10 0.13 0.11 0.34 0.21 0.14 0.13 0.38
Basic Earnings per Share		 ($1.23) ($1.06) $0.00 ($0.02) ($0.11) ($0.52) $0.91 ($4.51) ($1.17) $0.38
Weighted Average Basic Shares Outstanding		 354.20M 340.65M 375.42M 375.78M 382.48M 379.86M 230.95M 178.51M 292.49M 255.83M
Diluted Earnings per Share		 ($1.23) ($1.06) $0.00 ($0.02) ($0.11) ($0.52) $0.78 ($4.51) ($1.17) $0.51
Weighted Average Diluted Shares Outstanding		 354.20M 340.65M 375.42M 375.78M 382.48M 379.86M 282.53M 178.51M 292.49M 255.83M
Weighted Average Basic & Diluted Shares Outstanding		 374.53M 373.80M 376.57M 382.61M 386.02M 177.60M 177.78M 258.22M 279.25M 294.12M

Annual Cash Flow Statements for Core Scientific

This table details how cash moves in and out of Core Scientific's business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric 2020 2021 2022 2023 2024
Period end date 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024
Net Change in Cash & Equivalents		 1.81 123 -79 17 767
Net Cash From Operating Activities		 -24 -57 205 65 43
Net Cash From Continuing Operating Activities		 -24 -57 205 65 43
Net Income / (Loss) Continuing Operations		 -12 47 -2,146 -246 -1,315
Consolidated Net Income / (Loss)		 -12 47 -2,146 -246 -1,315
Depreciation Expense		 9.40 33 225 96 113
Amortization Expense		 1.30 1.37 7.97 1.19 11
Non-Cash Adjustments To Reconcile Net Income		 4.95 -75 2,058 47 1,264
Changes in Operating Assets and Liabilities, net		 -27 -64 60 167 -30
Net Cash From Investing Activities		 -15 -424 -591 -3.00 -95
Net Cash From Continuing Investing Activities		 -15 -425 -591 -3.00 -95
Purchase of Property, Plant & Equipment		 0.00 0.00 -384 -17 -95
Sale of Property, Plant & Equipment		 - 0.00 0.00 14 0.00
Divestitures		 - - 11 0.00 0.00
Other Investing Activities, net		 -1.48 -59 -218 0.00 0.00
Net Cash From Financing Activities		 41 604 306 -45 820
Net Cash From Continuing Financing Activities		 41 604 306 -45 820
Repayment of Debt		 -7.10 -49 -113 -45 -315
Repurchase of Common Equity		 0.00 - -32 0.00 0.00
Issuance of Debt		 45 671 261 0.00 1,078
Issuance of Common Equity		 - - 0.00 0.00 55
Other Financing Activities, net		 2.64 -18 190 0.00 1.50
Cash Interest Paid		 2.90 38 86 4.71 29
Cash Income Taxes Paid		 0.00 9.62 5.76 -0.37 -0.16

Quarterly Cash Flow Statements for Core Scientific

This table details how cash moves in and out of Core Scientific's business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric Q3 2022 Q4 2022 Q1 2023 Q2 2023 Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024
Period end date 9/30/2022 12/31/2022 3/31/2023 6/30/2023 9/30/2023 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024
Net Change in Cash & Equivalents		 -103 15 17 7.47 -13 5.77 45 -17 157 583
Net Cash From Operating Activities		 -52 116 20 18 5.43 22 22 1.20 5.71 14
Net Cash From Continuing Operating Activities		 -52 116 20 18 5.43 22 22 1.20 5.71 14
Net Income / (Loss) Continuing Operations		 -435 -435 -0.39 -9.26 -41 -196 211 -805 -455 -266
Consolidated Net Income / (Loss)		 -435 -435 -0.39 -9.26 -41 -196 211 -805 -455 -266
Depreciation Expense		 65 69 20 20 24 31 29 29 29 26
Amortization Expense		 2.57 1.37 0.20 0.27 0.23 0.49 1.43 2.45 2.29 4.51
Non-Cash Adjustments To Reconcile Net Income		 390 356 -7.76 14 15 26 -199 807 431 225
Changes in Operating Assets and Liabilities, net		 -74 124 7.81 -7.58 7.52 159 -20 -33 -1.46 24
Net Cash From Investing Activities		 -5.66 -139 -1.87 -0.62 -2.87 2.36 -32 -3.18 -31 -29
Net Cash From Continuing Investing Activities		 -5.66 -139 -1.87 -0.62 -2.87 2.36 -32 -3.18 -31 -29
Purchase of Property, Plant & Equipment		 -5.22 -140 -1.54 -0.95 -2.87 -12 -32 -3.14 -31 -29
Other Investing Activities, net		 -0.44 0.75 -0.33 0.33 - - -0.08 -0.05 -0.07 0.19
Net Cash From Financing Activities		 -45 38 -1.02 -9.95 -15 -18 54 -15 182 598
Net Cash From Continuing Financing Activities		 -45 38 -1.02 -9.95 -15 -18 54 -15 182 598
Repayment of Debt		 -78 14 -1.02 -9.95 -12 -22 -17 -11 -271 -15
Issuance of Debt		 -0.08 45 0.00 - - - 20 - 448 610
Other Financing Activities, net		 231 11 0.00 - -3.41 3.41 -3.38 -4.10 6.01 2.97
Cash Interest Paid		 24 16 0.32 0.43 0.77 3.20 2.81 15 8.10 2.62
Cash Income Taxes Paid		 -7.32 6.54 -0.30 -0.04 - -0.03 -0.00 -1.29 - 1.13

Annual Balance Sheets for Core Scientific

This table presents Core Scientific's assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric 2020 2021 2022 2023 2024
Period end date 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024
Total Assets		 0.02 2,439 808 712 1,599
Total Current Assets		 0.00 757 85 97 904
Cash & Equivalents		 0.00 118 16 50 836
Restricted Cash		 - 14 36 19 0.78
Accounts Receivable		 - 1.68 0.26 1.00 1.03
Other Current Assets		 - 593 0.72 26 66
Plant, Property, & Equipment, net		 0.00 0.00 691 585 556
Total Noncurrent Assets		 0.02 1,682 31 30 139
Other Noncurrent Operating Assets		 0.02 618 30 30 139
Total Liabilities & Shareholders' Equity		 0.02 2,439 808 712 1,599
Total Liabilities		 0.00 1,053 1,217 1,309 2,419
Total Current Liabilities		 0.00 320 187 488 135
Short-Term Debt		 - 104 36 124 16
Accounts Payable		 0.00 12 54 155 19
Accrued Expenses		 0.00 68 18 180 69
Current Deferred Revenue		 - 136 78 9.83 18
Other Current Liabilities		 - 0.00 0.77 20 12
Total Noncurrent Liabilities		 0.00 733 1,030 821 2,284
Long-Term Debt		 - 652 0.00 684 1,074
Capital Lease Obligations		 - 62 0.72 37 98
Other Noncurrent Operating Liabilities		 0.00 19 1,030 99 1,113
Commitments & Contingencies		 0.00 0.00 0.00 0.00 0.00
Total Equity & Noncontrolling Interests		 0.01 1,341 -409 -597 -820
Total Preferred & Common Equity		 0.01 1,341 -409 -597 -820
Preferred Stock		 0.00 - - 0.00 0.00
Total Common Equity		 0.01 1,341 -409 -597 -820
Common Stock		 0.03 1,380 1,764 1,823 2,915
Retained Earnings		 -0.01 -27 -2,174 -2,420 -3,735

Quarterly Balance Sheets for Core Scientific

This table presents Core Scientific's assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric Q3 2022 Q1 2023 Q2 2023 Q3 2023 Q1 2024 Q2 2024 Q3 2024
Period end date 9/30/2022 3/31/2023 6/30/2023 9/30/2023 3/31/2024 6/30/2024 9/30/2024
Total Assets		 1,404 760 751 705 814 761 922
Total Current Assets		 214 100 111 135 143 118 278
Cash & Equivalents		 30 47 58 42 98 96 253
Restricted Cash		 8.10 22 19 22 16 0.98 0.78
Accounts Receivable		 3.07 0.18 1.26 1.11 1.11 4.68 6.24
Other Current Assets		 173 31 33 34 28 16 18
Plant, Property, & Equipment, net		 1,156 628 608 547 576 550 550
Total Noncurrent Assets		 34 32 32 23 95 94 94
Other Noncurrent Operating Assets		 33 30 29 21 93 94 94
Total Liabilities & Shareholders' Equity		 1,404 760 751 705 814 761 922
Total Liabilities		 1,331 1,169 1,143 1,124 1,132 1,845 1,651
Total Current Liabilities		 1,289 215 187 313 138 75 77
Short-Term Debt		 978 36 28 128 23 18 18
Accounts Payable		 44 50 54 46 16 8.49 6.50
Accrued Expenses		 102 59 41 56 68 29 32
Current Deferred Revenue		 87 70 64 63 9.25 7.91 9.94
Other Current Liabilities		 78 0.60 0.42 20 21 11 10
Total Noncurrent Liabilities		 42 954 956 812 994 1,771 1,575
Long-Term Debt		 0.00 - 0.05 680 557 527 475
Capital Lease Obligations		 0.00 1.06 1.03 37 70 68 65
Other Noncurrent Operating Liabilities		 42 953 955 95 368 1,176 1,035
Commitments & Contingencies		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Equity & Noncontrolling Interests		 73 -409 -392 -419 -319 -1,084 -729
Total Preferred & Common Equity		 73 -409 -392 -419 -319 -1,084 -729
Preferred Stock		 - - - - 0.00 0.00 0.00
Total Common Equity		 73 -409 -392 -419 -319 -1,084 -729
Common Stock		 1,739 1,777 1,791 1,806 1,891 1,931 2,740
Retained Earnings		 -1,739 -2,185 -2,183 -2,225 -2,210 -3,014 -3,470

Annual Metrics and Ratios for Core Scientific

This table displays calculated financial ratios and metrics derived from Core Scientific's official financial filings.

Metric 2020 2021 2022 2023 2024
Period end date 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024
Growth Metrics		 - - - - -
Revenue Growth		 0.00% 904.71% 17.60% -21.54% 1.65%
EBITDA Growth		 0.00% 3,420.42% -1,320.57% 95.50% -1,298.35%
EBIT Growth		 0.00% 1,893.46% -1,889.85% 91.31% -610.67%
NOPAT Growth		 0.00% 2,327.02% -1,597.16% 100.42% -314.22%
Net Income Growth		 0.00% 487.61% -4,636.52% 88.52% -433.50%
EPS Growth		 0.00% 242.86% -3,250.00% 89.68% -575.38%
Operating Cash Flow Growth		 0.00% -138.73% 461.66% -68.27% -34.12%
Free Cash Flow Firm Growth		 0.00% 0.00% 151.71% -158.53% 206.23%
Invested Capital Growth		 0.00% 14,197,256.16% -120.49% 142.17% -361.96%
Revenue Q/Q Growth		 0.00% 0.00% -21.99% 4.29% -8.52%
EBITDA Q/Q Growth		 0.00% 0.00% -35.42% 77.58% -15.51%
EBIT Q/Q Growth		 0.00% 0.00% -34.39% 64.30% -13.68%
NOPAT Q/Q Growth		 0.00% 0.00% -53.83% 101.42% -178.28%
Net Income Q/Q Growth		 0.00% 0.00% -30.00% 49.25% -5.61%
EPS Q/Q Growth		 0.00% 0.00% -26.25% 45.38% 19.00%
Operating Cash Flow Q/Q Growth		 0.00% 0.00% 3.14% -59.15% -15.55%
Free Cash Flow Firm Q/Q Growth		 0.00% 0.00% 0.00% -343.69% -17.43%
Invested Capital Q/Q Growth		 0.00% 0.00% -141.92% -45.09% -10.28%
Profitability Metrics		 - - - - -
Gross Margin		 17.33% 43.87% 1.31% 24.57% 23.71%
EBITDA Margin		 7.87% 27.58% -286.28% -16.41% -225.72%
Operating Margin		 -11.67% 24.15% -329.46% 1.78% -3.76%
EBIT Margin		 -11.88% 21.20% -322.70% -35.75% -249.98%
Profit (Net Income) Margin		 -22.52% 8.69% -335.20% -49.06% -257.50%
Tax Burden Percent		 100.00% 75.01% 99.21% 100.28% 100.07%
Interest Burden Percent		 189.62% 54.64% 104.70% 136.84% 102.94%
Effective Tax Rate		 0.00% 24.99% 0.00% 0.00% 0.00%
Return on Invested Capital (ROIC)		 -30,334.93% 9.52% -179.19% 0.00% 0.00%
ROIC Less NNEP Spread (ROIC-NNEP)		 0.00% -5.42% -378.53% 0.00% 0.00%
Return on Net Nonoperating Assets (RNNOA)		 0.00% -2.69% -260.48% 0.00% 0.00%
Return on Equity (ROE)		 0.00% 6.83% -439.67% 48.99% 185.59%
Cash Return on Invested Capital (CROIC)		 0.00% -190.48% 0.00% -333.65% 0.00%
Operating Return on Assets (OROA)		 -42,913.33% 9.47% -127.29% -23.64% -110.48%
Return on Assets (ROA)		 -81,373.33% 3.88% -132.22% -32.44% -113.81%
Return on Common Equity (ROCE)		 0.00% 6.61% -419.64% 48.99% 185.59%
Return on Equity Simple (ROE_SIMPLE)		 0.00% 3.53% 524.33% 41.29% 160.33%
Net Operating Profit after Tax (NOPAT)		 -4.43 99 -1,477 6.27 -13
NOPAT Margin		 -8.17% 18.11% -230.62% 1.25% -2.63%
Net Nonoperating Expense Percent (NNEP)		 0.00% 14.94% 199.34% 66.45% 230.95%
Return On Investment Capital (ROIC_SIMPLE)		 - - 396.55% 2.52% -3.65%
Cost of Revenue to Revenue		 93.98% 56.13% 98.69% 75.43% 76.29%
SG&A Expenses to Revenue		 26.86% 11.11% 33.31% 18.69% 21.63%
R&D to Revenue		 9.73% 1.41% 4.21% 1.43% 2.32%
Operating Expenses to Revenue		 29.00% 19.72% 330.77% 22.79% 27.47%
Earnings before Interest and Taxes (EBIT)		 -6.44 115 -2,066 -180 -1,277
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 4.27 150 -1,833 -82 -1,153
Valuation Ratios		 - - - - -
Price to Book Value (P/BV)		 20,547.95 0.00 0.00 0.00 0.00
Price to Tangible Book Value (P/TBV)		 20,547.95 0.00 0.00 0.00 0.00
Price to Revenue (P/Rev)		 5.54 0.00 0.00 0.00 7.68
Price to Earnings (P/E)		 0.00 0.00 0.00 0.00 0.00
Dividend Yield		 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Yield		 0.00% 0.00% 0.00% 0.00% 0.00%
Enterprise Value to Invested Capital (EV/IC)		 20,547.95 0.00 0.00 0.00 0.00
Enterprise Value to Revenue (EV/Rev)		 5.54 0.00 0.00 0.00 8.37
Enterprise Value to EBITDA (EV/EBITDA)		 70.32 0.00 0.00 0.00 0.00
Enterprise Value to EBIT (EV/EBIT)		 0.00 0.00 0.00 0.00 0.00
Enterprise Value to NOPAT (EV/NOPAT)		 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Operating Cash Flow (EV/OCF)		 0.00 0.00 0.00 0.00 99.65
Enterprise Value to Free Cash Flow (EV/FCFF)		 0.00 0.00 0.00 0.00 6.74
Leverage & Solvency		 - - - - -
Debt to Equity		 0.00 0.59 -0.09 -1.42 -1.45
Long-Term Debt to Equity		 0.00 0.52 0.00 -1.21 -1.43
Financial Leverage		 0.00 0.50 0.69 -0.76 -0.80
Leverage Ratio		 1.03 1.76 3.33 -1.51 -1.63
Compound Leverage Factor		 1.95 0.96 3.48 -2.07 -1.68
Debt to Total Capital		 0.00% 37.14% -9.93% 339.97% 322.91%
Short-Term Debt to Total Capital		 0.00% 4.74% -9.73% 49.99% 4.43%
Long-Term Debt to Total Capital		 0.00% 32.40% -0.19% 289.98% 318.48%
Preferred Equity to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital		 0.00% 2.02% 0.00% 0.00% 0.00%
Common Equity to Total Capital		 100.00% 60.84% 109.93% -239.97% -222.91%
Debt to EBITDA		 0.00 5.45 -0.02 -10.26 -1.03
Net Debt to EBITDA		 0.00 4.58 0.01 -9.41 -0.30
Long-Term Debt to EBITDA		 0.00 4.76 0.00 -8.75 -1.02
Debt to NOPAT		 0.00 8.30 -0.03 134.82 -88.42
Net Debt to NOPAT		 0.00 6.97 0.01 123.71 -26.13
Long-Term Debt to NOPAT		 0.00 7.24 0.00 115.00 -87.21
Altman Z-Score		 452,195.72 0.00 0.00 0.00 -4.04
Noncontrolling Interest Sharing Ratio		 0.00% 3.21% 4.56% 0.00% 0.00%
Liquidity Ratios		 - - - - -
Current Ratio		 0.00 2.36 0.46 0.20 6.72
Quick Ratio		 0.00 0.37 0.09 0.11 6.22
Cash Flow Metrics		 - - - - -
Free Cash Flow to Firm (FCFF)		 0.00 -1,974 1,021 -597 635
Operating Cash Flow to CapEx		 0.00% 0.00% 53.44% 2,173.36% 45.06%
Free Cash Flow to Firm to Interest Expense		 0.00 -246.28 3,556.62 0.00 1,303.17
Operating Cash Flow to Interest Expense		 -17.83 -7.08 714.94 0.00 88.08
Operating Cash Flow Less CapEx to Interest Expense		 -17.83 -7.08 -622.97 0.00 -107.38
Efficiency Ratios		 - - - - -
Asset Turnover		 3,612.87 0.45 0.39 0.66 0.44
Accounts Receivable Turnover		 0.00 0.00 660.46 798.73 504.12
Inventory Turnover		 0.00 0.00 0.00 0.00 0.00
Fixed Asset Turnover		 0.00 0.00 0.00 0.79 0.89
Accounts Payable Turnover		 0.00 0.00 19.37 3.64 4.48
Days Sales Outstanding (DSO)		 0.00 0.00 0.55 0.46 0.72
Days Inventory Outstanding (DIO)		 0.00 0.00 0.00 0.00 0.00
Days Payable Outstanding (DPO)		 0.00 0.00 18.85 100.36 81.51
Cash Conversion Cycle (CCC)		 0.00 0.00 -18.29 -99.91 -80.79
Capital & Investment Metrics		 - - - - -
Invested Capital		 0.01 2,073 -425 179 -469
Invested Capital Turnover		 3,711.85 0.53 0.78 -4.09 -3.52
Increase / (Decrease) in Invested Capital		 0.00 2,073 -2,497 604 -648
Enterprise Value (EV)		 300 0.00 0.00 0.00 4,275
Market Capitalization		 300 0.00 0.00 0.00 3,924
Book Value per Share		 $0.00 $31.10 ($1.09) ($1.55) ($2.94)
Tangible Book Value per Share		 $0.00 $6.43 ($1.10) ($1.55) ($2.94)
Total Capital		 0.01 2,204 -372 249 368
Total Debt		 0.00 819 37 846 1,188
Total Long-Term Debt		 0.00 714 0.72 721 1,172
Net Debt		 0.00 687 -15 776 351
Capital Expenditures (CapEx)		 0.00 0.00 384 3.00 95
Debt-free, Cash-free Net Working Capital (DFCFNWC)		 -0.00 409 -118 -337 -51
Debt-free Net Working Capital (DFNWC)		 -0.00 541 -65 -267 786
Net Working Capital (NWC)		 -0.00 436 -102 -391 769
Net Nonoperating Expense (NNE)		 7.78 51 670 253 1,302
Net Nonoperating Obligations (NNO)		 0.00 687 -15 776 351
Total Depreciation and Amortization (D&A)		 11 35 233 97 124
Debt-free, Cash-free Net Working Capital to Revenue		 0.00% 75.12% -18.38% -67.03% -10.04%
Debt-free Net Working Capital to Revenue		 0.00% 99.31% -10.22% -53.15% 153.85%
Net Working Capital to Revenue		 0.00% 80.13% -15.88% -77.91% 150.66%
Earnings Adjustments		 - - - - -
Adjusted Basic Earnings per Share		 $0.00 ($0.83) ($6.30) ($0.65) ($4.39)
Adjusted Weighted Average Basic Shares Outstanding		 0.00 316.24M 340.65M 379.86M 255.83M
Adjusted Diluted Earnings per Share		 $0.00 ($0.83) ($6.30) ($0.65) ($4.39)
Adjusted Weighted Average Diluted Shares Outstanding		 0.00 316.24M 340.65M 379.86M 255.83M
Adjusted Basic & Diluted Earnings per Share		 $0.00 ($0.83) $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 0.00 8.50M 373.80M 177.60M 294.12M
Normalized Net Operating Profit after Tax (NOPAT)		 -8.55 125 -171 11 -10
Normalized NOPAT Margin		 -15.77% 22.96% -26.74% 2.14% -2.05%
Pre Tax Income Margin		 -22.52% 11.58% -337.87% -48.93% -257.34%
Debt Service Ratios		 - - - - -
EBIT to Interest Expense		 -4.83 14.40 -7,199.64 0.00 -2,621.33
NOPAT to Interest Expense		 -3.32 12.30 -5,145.25 0.00 -27.59
EBIT Less CapEx to Interest Expense		 -4.83 14.40 -8,537.55 0.00 -2,816.80
NOPAT Less CapEx to Interest Expense		 -3.32 12.30 -6,483.16 0.00 -223.06
Payout Ratios		 - - - - -
Dividend Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00%
Augmented Payout Ratio		 0.00% 0.00% -1.47% 0.00% 0.00%

Quarterly Metrics and Ratios for Core Scientific

This table displays calculated financial ratios and metrics derived from Core Scientific's official financial filings.

Metric Q3 2022 Q4 2022 Q1 2023 Q2 2023 Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024
Period end date 9/30/2022 12/31/2022 3/31/2023 6/30/2023 9/30/2023 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024
Growth Metrics		 - - - - - - - - - -
Revenue Growth		 43.69% -59.82% -37.33% -22.60% -30.55% 17.05% 49.05% 11.18% -15.54% -33.50%
EBITDA Growth		 -10,126.32% -414.78% 99.83% 101.49% 95.55% 78.38% 42,747.75% -6,645.19% -2,726.82% -196.78%
EBIT Growth		 -10,176.34% -557.91% 94.81% 98.90% 90.15% 74.57% 1,177.34% -8,516.31% -1,041.89% -139.23%
NOPAT Growth		 -8,489.92% -654.42% 128.45% 100.91% 97.00% 100.62% 936.81% -30.52% -242.24% -1,111.26%
Net Income Growth		 -2,514.66% -818.68% 99.92% 98.86% 90.54% 55.00% 54,401.80% -8,592.18% -1,006.45% -35.69%
EPS Growth		 -1,657.14% -524.00% 100.00% 99.20% 91.06% 50.94% 0.00% -22,450.00% -963.64% 198.08%
Operating Cash Flow Growth		 -15.35% 5.69% 651.65% -87.55% 110.44% -81.29% 11.19% -93.32% 5.13% -36.39%
Free Cash Flow Firm Growth		 0.00% 0.00% 239.76% 201.41% 167.74% -129.28% -122.22% -92.92% 6.50% 203.21%
Invested Capital Growth		 246.47% -120.49% -119.44% -130.95% -67.81% 142.17% 149.24% -29.02% -230.43% -361.96%
Revenue Q/Q Growth		 -0.85% -25.42% -0.49% 5.19% -11.04% 25.71% 26.71% -21.54% -32.42% -1.02%
EBITDA Q/Q Growth		 57.51% -9.91% 99.84% 2,033.22% -227.31% -433.62% 424.72% -396.69% 45.01% 43.98%
EBIT Q/Q Growth		 52.14% -8.98% 95.19% 56.11% -327.73% -181.47% 303.90% -450.99% 43.31% 41.03%
NOPAT Q/Q Growth		 61.61% -58.48% 101.20% 24.56% -227.19% 132.66% 1,903.52% -91.65% -726.52% 3.48%
Net Income Q/Q Growth		 46.35% -0.01% 99.91% -2,286.60% -344.34% -375.61% 207.66% -482.03% 43.44% 41.67%
EPS Q/Q Growth		 50.60% 13.82% 100.00% 0.00% -450.00% -372.73% 250.00% -678.21% 74.06% 143.59%
Operating Cash Flow Q/Q Growth		 -135.94% 322.74% -82.81% -9.56% -69.87% 299.39% 2.17% -94.57% 374.50% 141.64%
Free Cash Flow Firm Q/Q Growth		 45.70% 304.90% 32.37% -31.15% -63.72% -188.57% -0.68% 121.94% 445.71% -14.16%
Invested Capital Q/Q Growth		 -28.83% -141.92% -3.94% 0.21% 174.04% -45.09% 22.41% -361.48% 25.15% -10.28%
Profitability Metrics		 - - - - - - - - - -
Gross Margin		 -16.65% -38.96% 26.34% 29.12% 13.66% 27.69% 43.18% 27.51% -0.16% 5.05%
EBITDA Margin		 -203.64% -300.10% -0.50% 9.12% -13.06% -55.43% 142.05% -537.15% -437.06% -247.38%
Operating Margin		 -246.89% -524.60% 6.30% 7.46% -10.67% 2.77% 30.71% 4.66% -43.23% -42.15%
EBIT Margin		 -244.94% -357.90% -17.31% -7.22% -34.73% -77.76% 125.13% -559.78% -469.55% -279.75%
Profit (Net Income) Margin		 -267.45% -358.64% -0.32% -7.30% -36.44% -137.88% 117.16% -570.44% -477.44% -281.35%
Tax Burden Percent		 102.51% 95.29% 136.62% 101.41% 100.28% 100.17% 99.90% 100.02% 100.03% 100.14%
Interest Burden Percent		 106.51% 105.16% 1.36% 99.61% 104.65% 177.01% 93.72% 101.89% 101.65% 100.43%
Effective Tax Rate		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.10% 0.00% 0.00% 0.00%
Return on Invested Capital (ROIC)		 -217.36% -285.33% 2.74% 5.65% -5.37% 0.00% 0.00% 0.00% 0.00% 0.00%
ROIC Less NNEP Spread (ROIC-NNEP)		 -250.14% -282.23% 1.71% 2.33% -9.26% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Net Nonoperating Assets (RNNOA)		 -639.58% -194.21% 2.65% 93.18% 45.11% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Equity (ROE)		 -856.93% -479.54% 5.39% 98.83% 39.74% 48.99% 9.74% 112.58% 216.90% 185.59%
Cash Return on Invested Capital (CROIC)		 0.00% 0.00% 0.00% 0.00% 36.61% -333.65% -284.87% 0.00% 0.00% 0.00%
Operating Return on Assets (OROA)		 -229.65% -141.18% -5.68% -2.96% -15.86% -51.41% 89.29% -426.24% -322.14% -123.64%
Return on Assets (ROA)		 -250.74% -141.47% -0.11% -2.99% -16.64% -91.16% 83.60% -434.35% -327.55% -124.34%
Return on Common Equity (ROCE)		 -51.36% -457.69% 5.39% 98.83% 39.74% 48.99% 9.74% 112.58% 216.90% 185.59%
Return on Equity Simple (ROE_SIMPLE)		 -2,260.76% 0.00% 411.12% 224.06% 115.98% 0.00% 11.12% 76.67% 170.71% 0.00%
Net Operating Profit after Tax (NOPAT)		 -281 -445 5.32 6.63 -8.43 2.75 55 4.61 -29 -28
NOPAT Margin		 -172.82% -367.22% 4.41% 5.22% -7.47% 1.94% 30.68% 3.26% -30.26% -29.51%
Net Nonoperating Expense Percent (NNEP)		 32.79% -3.10% 1.03% 3.31% 3.88% 52.17% -61.81% 346.20% 81.31% 42.18%
Return On Investment Capital (ROIC_SIMPLE)		 - 119.57% - - - 1.11% - - - -7.57%
Cost of Revenue to Revenue		 116.65% 138.96% 73.66% 70.88% 86.34% 72.31% 56.52% 72.49% 100.16% 95.53%
SG&A Expenses to Revenue		 26.66% 32.08% 18.04% 19.22% 20.82% 17.08% 7.86% 18.60% 36.03% 37.83%
R&D to Revenue		 3.81% 2.19% 1.17% 1.29% 2.00% 1.32% 1.00% 1.54% 2.98% 5.31%
Operating Expenses to Revenue		 230.24% 485.64% 20.04% 21.66% 24.32% 24.92% 12.77% 22.85% 43.06% 46.62%
Earnings before Interest and Taxes (EBIT)		 -398 -434 -21 -9.17 -39 -110 225 -790 -448 -264
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 -331 -364 -0.60 12 -15 -79 255 -758 -417 -233
Valuation Ratios		 - - - - - - - - - -
Price to Book Value (P/BV)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Price to Tangible Book Value (P/TBV)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Price to Revenue (P/Rev)		 0.00 0.00 0.00 0.00 0.00 0.00 1.12 2.87 5.49 7.68
Price to Earnings (P/E)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Dividend Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Enterprise Value to Invested Capital (EV/IC)		 0.00 0.00 0.00 0.00 0.00 0.00 5.36 0.00 0.00 0.00
Enterprise Value to Revenue (EV/Rev)		 0.00 0.00 0.00 0.00 0.00 0.00 2.07 3.77 6.03 8.37
Enterprise Value to EBITDA (EV/EBITDA)		 0.00 0.00 0.00 0.00 0.00 0.00 6.71 0.00 0.00 0.00
Enterprise Value to EBIT (EV/EBIT)		 0.00 0.00 0.00 0.00 0.00 0.00 17.57 0.00 0.00 0.00
Enterprise Value to NOPAT (EV/NOPAT)		 0.00 0.00 0.00 0.00 0.00 0.00 29.40 57.71 196.14 0.00
Enterprise Value to Operating Cash Flow (EV/OCF)		 0.00 0.00 0.00 0.00 0.00 0.00 17.29 42.94 66.28 99.65
Enterprise Value to Free Cash Flow (EV/FCFF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 13.11 4.38 6.74
Leverage & Solvency		 - - - - - - - - - -
Debt to Equity		 13.39 -0.09 -0.09 -0.07 -2.02 -1.42 -2.04 -0.57 -0.76 -1.45
Long-Term Debt to Equity		 0.00 0.00 0.00 0.00 -1.71 -1.21 -1.97 -0.55 -0.74 -1.43
Financial Leverage		 2.56 0.69 1.55 39.93 -4.87 -0.76 -0.69 -0.32 -0.91 -0.80
Leverage Ratio		 4.77 3.33 4.82 108.12 -6.10 -1.51 -2.16 -1.02 -1.42 -1.63
Compound Leverage Factor		 5.08 3.50 0.07 107.69 -6.39 -2.67 -2.03 -1.04 -1.44 -1.64
Debt to Total Capital		 93.05% -9.93% -9.86% -7.91% 198.27% 339.97% 196.06% -130.06% -325.26% 322.91%
Short-Term Debt to Total Capital		 93.05% -9.73% -9.58% -7.62% 30.11% 49.99% 7.04% -3.90% -10.46% 4.43%
Long-Term Debt to Total Capital		 0.00% -0.19% -0.28% -0.30% 168.15% 289.98% 189.02% -126.16% -314.80% 318.48%
Preferred Equity to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Common Equity to Total Capital		 6.95% 109.93% 109.86% 107.91% -98.27% -239.97% -96.06% 230.06% 425.26% -222.91%
Debt to EBITDA		 -0.72 -0.02 -0.02 -0.04 -2.30 -10.26 3.74 -1.03 -0.56 -1.03
Net Debt to EBITDA		 -0.69 0.01 0.02 0.07 -2.12 -9.41 3.09 -0.87 -0.30 -0.30
Long-Term Debt to EBITDA		 0.00 0.00 0.00 0.00 -1.95 -8.75 3.61 -1.00 -0.54 -1.02
Debt to NOPAT		 -1.02 -0.03 -0.03 -0.04 -1.91 134.82 16.41 16.30 32.50 -88.42
Net Debt to NOPAT		 -0.98 0.01 0.02 0.07 -1.77 123.71 13.53 13.72 17.72 -26.13
Long-Term Debt to NOPAT		 0.00 0.00 0.00 0.00 -1.62 115.00 15.82 15.81 31.46 -87.21
Altman Z-Score		 0.00 0.00 0.00 0.00 0.00 0.00 -1.86 -7.60 -4.89 -1.95
Noncontrolling Interest Sharing Ratio		 94.01% 4.56% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Liquidity Ratios		 - - - - - - - - - -
Current Ratio		 0.17 0.46 0.47 0.59 0.43 0.20 1.04 1.58 3.63 6.72
Quick Ratio		 0.03 0.09 0.22 0.31 0.14 0.11 0.72 1.35 3.39 6.22
Cash Flow Metrics		 - - - - - - - - - -
Free Cash Flow to Firm (FCFF)		 -1,002 2,052 2,717 1,870 678 -601 -603 132 723 620
Operating Cash Flow to CapEx		 -997.93% 82.71% 1,295.78% 1,900.42% 189.47% 186.48% 69.52% 38.41% 18.33% 47.62%
Free Cash Flow to Firm to Interest Expense		 0.00 7,150.46 0.00 0.00 0.00 -561.60 -12,069.80 1,103.41 2,279.39 0.00
Operating Cash Flow to Interest Expense		 0.00 404.13 0.00 0.00 0.00 20.28 443.48 10.03 18.02 0.00
Operating Cash Flow Less CapEx to Interest Expense		 0.00 -84.46 0.00 0.00 0.00 9.41 -194.40 -16.09 -80.32 0.00
Efficiency Ratios		 - - - - - - - - - -
Asset Turnover		 0.94 0.39 0.33 0.41 0.46 0.66 0.71 0.76 0.69 0.44
Accounts Receivable Turnover		 0.00 660.46 1,659.71 222.52 230.49 798.73 876.10 194.02 151.83 504.12
Inventory Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Fixed Asset Turnover		 0.00 0.00 0.79 0.64 0.57 0.79 0.93 0.99 1.02 0.89
Accounts Payable Turnover		 28.14 19.37 18.14 12.60 9.98 3.64 11.78 12.94 15.46 4.48
Days Sales Outstanding (DSO)		 0.00 0.55 0.22 1.64 1.58 0.46 0.42 1.88 2.40 0.72
Days Inventory Outstanding (DIO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Payable Outstanding (DPO)		 12.97 18.85 20.13 28.97 36.57 100.36 30.99 28.22 23.62 81.51
Cash Conversion Cycle (CCC)		 -12.97 -18.29 -19.91 -27.33 -34.99 -99.91 -30.57 -26.33 -21.21 -80.79
Capital & Investment Metrics		 - - - - - - - - - -
Invested Capital		 1,013 -425 -441 -440 326 179 217 -568 -425 -469
Invested Capital Turnover		 1.26 0.78 0.62 1.08 0.72 -4.09 -5.01 -1.14 -11.25 -3.52
Increase / (Decrease) in Invested Capital		 721 -2,497 -2,711 -1,864 -687 604 659 -128 -751 -648
Enterprise Value (EV)		 0.00 0.00 0.00 0.00 0.00 0.00 1,165 2,169 3,367 4,275
Market Capitalization		 0.00 0.00 0.00 0.00 0.00 0.00 629 1,653 3,063 3,924
Book Value per Share		 $0.20 ($1.09) ($1.09) ($1.04) ($1.09) ($1.55) ($1.79) ($6.10) ($2.82) ($2.94)
Tangible Book Value per Share		 $0.20 ($1.10) ($1.10) ($1.05) ($1.10) ($1.55) ($1.81) ($6.10) ($2.82) ($2.94)
Total Capital		 1,051 -372 -372 -364 426 249 332 -471 -172 368
Total Debt		 978 37 37 29 845 846 650 613 558 1,188
Total Long-Term Debt		 0.00 0.72 1.06 1.08 717 721 627 594 540 1,172
Net Debt		 940 -15 -33 -48 781 776 536 516 304 351
Capital Expenditures (CapEx)		 5.22 140 1.54 0.95 2.87 12 32 3.14 31 29
Debt-free, Cash-free Net Working Capital (DFCFNWC)		 -135 -118 -148 -125 -114 -337 -86 -36 -35 -51
Debt-free Net Working Capital (DFNWC)		 -98 -65 -79 -48 -50 -267 29 61 219 786
Net Working Capital (NWC)		 -1,075 -102 -115 -76 -178 -391 5.18 43 201 769
Net Nonoperating Expense (NNE)		 154 -10 5.71 16 33 198 -156 810 426 238
Net Nonoperating Obligations (NNO)		 940 -15 -33 -48 745 776 536 516 304 351
Total Depreciation and Amortization (D&A)		 67 70 20 21 24 32 30 32 31 31
Debt-free, Cash-free Net Working Capital to Revenue		 -16.50% -18.38% -26.07% -23.57% -23.57% -67.03% -15.27% -6.20% -6.18% -10.04%
Debt-free Net Working Capital to Revenue		 -11.92% -10.22% -13.88% -9.12% -10.30% -53.15% 5.08% 10.67% 39.28% 153.85%
Net Working Capital to Revenue		 -131.01% -15.88% -20.15% -14.34% -36.94% -77.91% 0.92% 7.48% 36.07% 150.66%
Earnings Adjustments		 - - - - - - - - - -
Adjusted Basic Earnings per Share		 ($1.23) ($1.06) ($0.03) ($0.02) ($0.11) ($0.52) $0.91 ($4.51) ($1.17) $0.38
Adjusted Weighted Average Basic Shares Outstanding		 354.20M 340.65M 375.42M 375.78M 382.48M 379.86M 230.95M 178.51M 292.49M 255.83M
Adjusted Diluted Earnings per Share		 ($1.23) ($1.06) ($0.03) ($0.02) ($0.11) ($0.52) $0.78 ($4.51) ($1.17) $0.51
Adjusted Weighted Average Diluted Shares Outstanding		 354.20M 340.65M 375.42M 375.78M 382.48M 379.86M 282.53M 178.51M 292.49M 255.83M
Adjusted Basic & Diluted Earnings per Share		 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 374.53M 373.80M 376.57M 382.61M 386.02M 177.60M 177.78M 258.22M 279.25M 294.12M
Normalized Net Operating Profit after Tax (NOPAT)		 -54 -63 5.32 6.89 -7.97 6.49 59 4.42 -28 -28
Normalized NOPAT Margin		 -33.01% -51.88% 4.41% 5.43% -7.06% 4.58% 32.80% 3.13% -29.89% -29.40%
Pre Tax Income Margin		 -260.90% -376.36% -0.24% -7.19% -36.34% -137.64% 117.27% -570.33% -477.30% -280.95%
Debt Service Ratios		 - - - - - - - - - -
EBIT to Interest Expense		 0.00 -1,512.05 0.00 0.00 0.00 -103.15 4,500.68 -6,582.14 -1,412.42 0.00
NOPAT to Interest Expense		 0.00 -1,551.41 0.00 0.00 0.00 2.57 1,103.46 38.38 -91.02 0.00
EBIT Less CapEx to Interest Expense		 0.00 -2,000.63 0.00 0.00 0.00 -114.02 3,862.80 -6,608.27 -1,510.76 0.00
NOPAT Less CapEx to Interest Expense		 0.00 -2,040.00 0.00 0.00 0.00 -8.30 465.58 12.25 -189.36 0.00
Payout Ratios		 - - - - - - - - - -
Dividend Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Augmented Payout Ratio		 0.00% -1.47% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%

Frequently Asked Questions About Core Scientific's Financials

When does Core Scientific's financial year end?

According to the most recent income statement we have on file, Core Scientific's fiscal year ends in December. Their fiscal year 2024 ended on December 31, 2024.

How has Core Scientific's net income changed over the last 4 years?

Core Scientific's net income appears to be on an upward trend, with a most recent value of -$1.32 billion in 2024, rising from -$12.21 million in 2020. The previous period was -$246.49 million in 2023. See Core Scientific's forecast for analyst expectations on what’s next for the company.

What is Core Scientific's operating income?
Core Scientific's total operating income in 2024 was -$19.20 million, based on the following breakdown:
  • Total Gross Profit: $121.07 million
  • Total Operating Expenses: $140.27 million
How has Core Scientific revenue changed over the last 4 years?

Over the last 4 years, Core Scientific's total revenue changed from $54.19 million in 2020 to $510.67 million in 2024, a change of 842.3%.

How much debt does Core Scientific have?

Core Scientific's total liabilities were at $2.42 billion at the end of 2024, a 84.8% increase from 2023, and a 604,748,650.0% increase since 2020.

How much cash does Core Scientific have?

In the past 4 years, Core Scientific's cash and equivalents has ranged from $0.00 in 2020 to $836.20 million in 2024, and is currently $836.20 million as of their latest financial filing in 2024.

How has Core Scientific's book value per share changed over the last 4 years?

Over the last 4 years, Core Scientific's book value per share changed from 0.00 in 2020 to -2.94 in 2024, a change of -2,937,100.0%.


Related Companies

This page (NASDAQ:CORZ) was last updated on 5/7/2025 by MarketBeat.com Staff
From Our Partners
3..2..1.. AI 2.0 ignition (don’t sleep on this)
I just put together an urgent new presentation that you need to see right away. In short: I believe we are...
Timothy Sykes | Sponsored
Trump to solve American wealth loss?
Is President Trump’s Executive Order 14179… A secret way to restore wealth for good citizens? If you’ve ...
Paradigm Press | Sponsored
Trump’s treachery
Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...
Porter & Company | Sponsored
URGENT: This Altcoin Opportunity Won’t Wait – Act Now
My friends Joel and Adam have a simple motto: "For us, it's always a bull market." That’s because their 92%...
Crypto Swap Profits | Sponsored
Elon Set to Shock the World on June 1st?
Tech legend Jeff Brown recently traveled to the industrial zone of South Memphis to investigate what he believ...
Brownstone Research | Sponsored
Gold Alert: The Truth About Fort Knox Is Coming
Owning physical gold isn’t the best way to profit. I’ve found a better way to invest in gold—one that’s alr...
Golden Portfolio | Sponsored
The Robotics Revolution has arrived … and one $7 stock could take off as a result.
Robots aren't coming to America in 2025. They are already here. Oxford Economics says, "The Robotics Rev...
Weiss Ratings | Sponsored
What President Trump’s Executive Order 14154 means for your money
Nearly $3 trillion disappeared from the stock market on Thursday morning. According to Whitney Tilson - a f...
Stansberry Research | Sponsored